stoxline Quote Chart Rank Option Currency Glossary
  
Amgen Inc. (AMGN)
296.66  1.87 (0.63%)    02-11 16:14
Open: 290.56
High: 297.945
Volume: 2,975,948
  
Pre. Close: 294.79
Low: 288.36
Market Cap: 159,465(M)
Technical analysis
2025-02-11 4:43:10 PM
Short term     
Mid term     
Targets 6-month :  361.12 1-year :  421.79
Resists First :  309.17 Second :  361.12
Pivot price 288.67
Supports First :  278.38 Second :  259.35
MAs MA(5) :  295.35 MA(20) :  284.44
MA(100) :  293.98 MA(250) :  299.5
MACD MACD :  6.7 Signal :  5.5
%K %D K(14,3) :  62.3 D(3) :  62.6
RSI RSI(14): 63.6
52-week High :  346.85 Low :  253.3
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AMGN ] has closed below upper band by 26.5%. Bollinger Bands are 30.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 298.45 - 299.88 299.88 - 301.17
Low: 284.85 - 286.51 286.51 - 288.01
Close: 293.9 - 296.65 296.65 - 299.15
Company Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Headline News

Tue, 11 Feb 2025
JSF Financial LLC Has $676,000 Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat

Tue, 11 Feb 2025
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Equitable Trust Co. - MarketBeat

Tue, 11 Feb 2025
Amgen Inc. (NASDAQ:AMGN) Stake Lowered by Core Alternative Capital - MarketBeat

Tue, 11 Feb 2025
Kingsview Wealth Management LLC Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat

Mon, 10 Feb 2025
Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript - MSN

Mon, 10 Feb 2025
Is Trending Stock Amgen Inc. (AMGN) a Buy Now? - Yahoo Finance Australia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 538 (M)
Shares Float 536 (M)
Held by Insiders 0.2 (%)
Held by Institutions 80.7 (%)
Shares Short 11,430 (K)
Shares Short P.Month 11,530 (K)
Stock Financials
EPS 7.82
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 14
Profit Margin 13 %
Operating Margin 24.1 %
Return on Assets (ttm) 4.5 %
Return on Equity (ttm) 55.7 %
Qtrly Rev. Growth 23.2 %
Gross Profit (p.s.) 36.66
Sales Per Share 60.51
EBITDA (p.s.) 22.78
Qtrly Earnings Growth 62 %
Operating Cash Flow 7,260 (M)
Levered Free Cash Flow 4,570 (M)
Stock Valuations
PE Ratio 37.93
PEG Ratio 0
Price to Book value 21.19
Price to Sales 4.9
Price to Cash Flow 21.96
Stock Dividends
Dividend 2.25
Forward Dividend 0
Dividend Yield 0.7%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android